172 related articles for article (PubMed ID: 11293286)
1. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
Visser JH; Wessels G; Hesseling PB; Louw I; Oberholster E; Mansvelt EP
Pediatr Hematol Oncol; 2001; 18(3):187-91. PubMed ID: 11293286
[TBL] [Abstract][Full Text] [Related]
2. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Yetgin S; Cetin M
Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
[TBL] [Abstract][Full Text] [Related]
3. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
4. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
5. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
6. Prognostic variables and survival in pediatric acute lymphoblastic leukemias: cancer institute experience.
Shanta V; Maitreyan V; Sagar TG; Gajalakshmi CK; Rajalekshmy KR
Pediatr Hematol Oncol; 1996; 13(3):205-16. PubMed ID: 8735336
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
8. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Chappell R; Hammond D; Bleyer WA
J Clin Oncol; 1996 Feb; 14(2):389-98. PubMed ID: 8636748
[TBL] [Abstract][Full Text] [Related]
9. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
[TBL] [Abstract][Full Text] [Related]
10. [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
Derwich K; Kaczmarek-Kanold M; Wachowiak J; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Jackowska T; Kołtan A; Cwiklińska M; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A
Przegl Lek; 2004; 61 Suppl 2():49-52. PubMed ID: 15686046
[TBL] [Abstract][Full Text] [Related]
11. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
Schultz KR; Massing B; Spinelli JJ; Gaynon PS; Wadsworth L
Med Pediatr Oncol; 1997 Jul; 29(1):16-22. PubMed ID: 9142200
[TBL] [Abstract][Full Text] [Related]
12. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Pedrosa F; Coustan-Smith E; Zhou Y; Cheng C; Pedrosa A; Lins MM; Pedrosa M; Lucena-Silva N; Ramos AML; Vinhas E; Rivera GK; Campana D; Ribeiro RC
Blood; 2020 Apr; 135(17):1458-1466. PubMed ID: 32027741
[TBL] [Abstract][Full Text] [Related]
13. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
[TBL] [Abstract][Full Text] [Related]
14. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
[TBL] [Abstract][Full Text] [Related]
15. Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.
Janka-Schaub GE; Goebel U; Graubner U; Haas RJ; Juergens H; Spaar HJ; Winkler K
Haematol Blood Transfus; 1990; 33():489-93. PubMed ID: 2182442
[No Abstract] [Full Text] [Related]
16. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Dunphy CH; Kitchen S; Saravia O; Velasquez WS
Am J Hematol; 1996 Jan; 51(1):85-9. PubMed ID: 8571944
[TBL] [Abstract][Full Text] [Related]
17. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
Attarbaschi A; Mann G; Zimmermann M; Bader P; Barisone E; Basso G; Biondi A; Cario G; Cazzaniga G; Colombini A; Flotho C; Kuhlen M; Lang P; Lauten M; Linderkamp C; Locatelli F; Lo Nigro L; Möricke A; Niggli F; Panzer-Grümayer R; Parasole R; Peters C; Caterina Putti M; Rizzari C; Suttorp M; Valsecchi MG; Conter V; Schrappe M;
Leukemia; 2020 Jun; 34(6):1694-1700. PubMed ID: 31806872
[No Abstract] [Full Text] [Related]
18. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
19. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Gaiger A; Linnerth B; Mann G; Schmid D; Heinze G; Tisljar K; Haas OA; Gadner H; Lion T
Eur J Haematol; 1999 Aug; 63(2):86-93. PubMed ID: 10480287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
